Astrocytoma, Grade IV
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CelularityFLORHAM PARK, NJ
2 programs1
1
CYNK-001 systemic and Intra cavity administrationPhase 1/21 trial
CYNK001-IVPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
CelularityCYNK-001 systemic and Intra cavity administration
CelularityCYNK001-IV
Clinical Trials (2)
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
Start: Mar 2022Est. completion: May 2024
Phase 1/2Withdrawn
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Start: Oct 2020Est. completion: Aug 2021
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space